Business
Oncolytics Biotech® to Participate in BIO Investor Forum Digital
Oncolytics Biotech® to Participate in BIO Investor Forum Digital Canada Ne...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics\n \n \n \n Oncolytics Biotech® to Participate in BIO Investor Forum Digital\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n SAN DIEGO and CALGARY, AB, Oct. 7, 2020\n \n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n ,\n \n Oct. 7, 2020\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be participating in the BIO Investor Forum Digital, which is taking place virtually from\n \n October 13-15, 2020\n \n .\n \n \n \n \n \n The Company's profile for the forum is available\n \n here\n \n . Registered attendees will be able to view an on-demand corporate overview provided by President and Chief Executive Officer Dr.\n \n Matt Coffey\n \n . Company management will also be participating in one-on-one investor meetings at the forum. To schedule a meeting, please submit a meeting request on the forum website, or email\n \n [email protected]\n \n .\n \n \n \n About Oncolytics Biotech Inc.\n \n \n \n Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning \"cold\" tumors \"hot\" -- through innate and adaptive immune responses to treat a variety of cancers.\n \n \n Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit:\n \n www.oncolytic...